Open drug discovery in Alzheimer's disease

Open drug discovery in Alzheimer's disease

Abstract Alzheimer's disease (AD) drug discovery has focused on a set of highly studied therapeutic hypotheses, with limited success. The heterogeneous nature of AD processes suggests that a more diverse, systems‐integrated strategy may identify new therapeutic hypotheses. Although many target...

Full description

Bibliographic Details
Main Authors: Alison D. Axtman, Paul E. Brennan, Tristan Frappier‐Brinton, Ranjita Betarbet, Gregory W. Carter, Haian Fu, Opher Gileadi, Anna K. Greenwood, Karina Leal, Frank M. Longo, Lara M. Mangravite, Aled M. Edwards, Allan I. Levey, The Emory‐Sage‐SGC TREAT‐AD Center
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
drug development
drug targets
genomics
proteomics
systems biology
Online Access:https://doi.org/10.1002/trc2.12394

Internet

https://doi.org/10.1002/trc2.12394

Similar Items